Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1595043 (Single-blind, Partially Randomised, Placebo-controlled, Parallel (Sequential) Group Design) in Healthy Male Subjects
Latest Information Update: 23 Feb 2024
At a glance
- Drugs BI 1595043 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 23 Mar 2021 Status changed from active, no longer recruiting to completed.
- 16 Mar 2021 Planned End Date changed from 17 Mar 2021 to 20 Mar 2021.
- 16 Mar 2021 Planned primary completion date changed from 17 Mar 2021 to 20 Mar 2021.